AVRO Stock Summary and Trading Ideas (Avrobio | NASDAQ:AVRO)

Avrobio Inc is a clinical-stage gene therapy company. The company is engaged in developing potentially curative ex vivo lentiviral gene therapies to treat rare diseases following a single-dose treatment regimen. The company's pipeline includes AVR-RD-04 for the treatment of cystinosis; AVR-RD-02 for the treatment of Gaucher disease type 1; AVR-RD-05 for the treatment of Hunter syndrome; and AVR-RD-03 for the treatment of Pompe disease.

Avrobio trades on the NASDAQ stock market under the symbol AVRO.

As of May 16, 2024, AVRO stock price climbed to $1.39 with 169,731 million shares trading.

AVRO has a beta of 0.89, meaning it tends to be less sensitive to market movements. AVRO has a correlation of 0.02 to the broad based SPY ETF.

AVRO has a market cap of $62.36 million. This is considered a Micro Cap stock.

In the last 3 years, AVRO stock traded as high as $11.00 and as low as $.56.

The top ETF exchange traded funds that AVRO belongs to (by Net Assets): VTI, VXF.

AVRO has outperformed the market in the last year with a price return of +124.2% while the SPY ETF gained +29.6%. AVRO has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +6.1% and +13.9%, respectively, while the SPY returned +5.6% and +5.7%, respectively.

AVRO support price is $1.33 and resistance is $1.41 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AVRO stock will trade within this expected range on the day.